Christopher Von Seggern - Mar 11, 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Commercial Officer
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Mar 11, 2024
Transactions value $
$0
Form type
4
Date filed
3/12/2024, 06:42 PM
Previous filing
Mar 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Award $0 +100K $0.00 100K Mar 11, 2024 Common Shares 100K $44.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.